Skip to main content

Nilotinib News

FDA Approves Danziten (nilotinib) Tablets, the First and Only Nilotinib With No Mealtime Restrictions

WOBURN, Mass. Nov 14, 2024 – Azurity Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved Danziten, the first and only nilotinib with no mealtime restrictions ...

Novartis Drug Tasigna Approved by FDA to Treat Children with Rare Form of Leukemia

Basel, March 22, 2018 - Novartis announced today that the US Food and Drug Administration (FDA) expanded the indication for Tasigna (nilotinib) to include treatment of first- and second-line...

FDA Updates the Label of Tasigna to Reflect that Certain Patients with a Type of Leukemia May be Eligible to Stop Treatment After Sustained Response

December 22, 2017 – The U.S. Food and Drug Administration today updated the product label for the cancer drug Tasigna (nilotinib) to include information for providers about how to discontinue the...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Chronic Myelogenous Leukemia (CML)

Nilotinib patient information at Drugs.com